Sepsis is not an infection; it’s your body's dysregulated response to one.

In this episode, Ajay Shah, CEO and co-founder of CytoVale, discusses his company’s groundbreaking technology, IntelliSep, which swiftly identifies patients at risk of sepsis in just eight minutes, as delays can significantly impact patient outcomes. Unlike traditional methods relying on vague symptoms, IntelliSep directly assesses white blood cells, offering a clear, objective diagnosis. Ajay highlights CytoVale's FDA-approved technology as a game-changer in emergency departments, where identifying sepsis quickly is critical, and explains the economic benefits for hospitals, citing significant savings per patient tested. Finally, he addresses the potential use of IntelliSep in urgent care centers, envisioning it as a tool to guide patients to appropriate care settings efficiently.

Tune in to learn more about this revolutionary approach to sepsis detection and its potential impact on healthcare outcomes!

Resources:

Watch the entire interview here.
Connect with and follow Ajay Shah on LinkedIn here.
Learn more about CytoVale on LinkedIn and their website.
Discover more about CytoVale’s IntelliSep here.

Episode #43: Less is More: Small Bay Industrial